← Back to Clinical Trials
Recruiting NCT06771193

NCT06771193 Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06771193
Status Recruiting
Phase
Sponsor MSD Italia S.r.l.
Condition Cervical Cancer
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2024-12-17
Primary Completion 2025-12

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2024-12-17 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.

Eligibility Criteria

Inclusion Criteria: * Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF) * Age ≥18 years * Diagnosis of a cervical cancer * Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease * Any treatment received between January 2018 and December 2021 for advanced disease Exclusion Criteria: * Patients participating in a pharmacological clinical trial for the treatment of advanced disease * Patients who participated in a clinical trial * Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs

Contact & Investigator

Central Contact

Stefania Lopez

✉ info.studiclinici@opisresearch.com

📞 +39 03626331

Frequently Asked Questions

Who can join the NCT06771193 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06771193 currently recruiting?

Yes, NCT06771193 is actively recruiting participants. Contact the research team at info.studiclinici@opisresearch.com for enrollment information.

Where is the NCT06771193 trial being conducted?

This trial is being conducted at Bologna, Italy, Catania, Italy, Genova, Italy, Milan, Italy and 7 additional locations.

Who is sponsoring the NCT06771193 clinical trial?

NCT06771193 is sponsored by MSD Italia S.r.l.. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology